Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Metavante completes GHR Systems acquisition
10. Metavante completes TREEV acquisition
11. Johnson Controls completes sale of French unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. (PRWEB) August 21, 2014 The ... the first private college in the Mid-Hudson Region to ... will now begin accepting applications from qualified “high-technology” businesses ... “We are very pleased to have been selected for ... Governor Cuomo’s transformative initiative to stimulate economic development in ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced today ... 2007 highlights, Major pipeline progress:, - ... cSSSI,achieves its pre-specified primary endpoint, as did the first, ... intravenous iclaprim in,cSSSI initiated, - First patients enrolled ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the management of ... SURGICAL IMPLANT is a biodegradable and fully,bioresorbable ...
... 13 Kansas has long,been known for its ... many have not realized, however, is that Kansas, ... far beyond the farm,-- namely, the scientific laboratory., ... and the,animal-health industry have positioned the state squarely ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... rainforests are often called the "lungs of the planet" because ... But the amount of carbon dioxide that rainforests absorb, or ... a paper published online this week (Feb 6 2013) by ... from the University of Exeter, the Met Office-Hadley Centre and ...
... A closer look at personalized or point-of-care healthcare ... in India organized and chaired by NJIT Distinguished ... Medicine and Biology Society (EMBS) International Special Topic ... the world, focused on topics ranging from 21st ...
... Virginia Commonwealth University Massey Cancer Center suggest that a ... potentially be an effective new therapy for several forms ... and mantle cell lymphoma (MCL). The study, ... showed that the experimental drug combination killed cancer cells ...
Cached Biology News:Lungs of the planet reveal their true sensitivity to global warming 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 3Experimental drug combination selectively destroys lymphoma cells 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... to a lesser extent in breast, lung ... Ab-2 shows no cross-reaction with MUC1 and ... the human MUC3 Immunogen: MUC3 ...
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: